A funny story from EHA2023 – Amer Zeidan

A funny story from EHA2023: After I gave a presentation on new therapies for MDS, someone asked me if I was aware of the newly published IWG2023 response criteria for higher risk MDS & how applying them would potentially affect the reported responses for one of the therapies I covered which used the old 2006 criteria!

I didn’t want to embarrass the person who asked the question by pointing out that I was the lead author on the revised response criteria paper & just said that I am well aware of the criteria, but it was quite hilarious for the people who witnessed the exchange!

Source: Amer Zeidan / Twitter

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.